


In the Claims

Please amend the claims of the above-identified application as follows.

1. **(original)** Compound in the form of pure enantiomer or in the form of a mixture of enantiomers, complying with the general formula (I)



in which R represents a halogen atom or a (C₃-C₆)cycloalkyl group or a phenyl group substituted by one or more groups chosen from a halogen atom, or a (C₁-C₆)alkyl, (C₁-C₆)alkoxy, nitro, amino, (C₁-C₃)dialkylamino, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, acetyl or methylenedioxy group, or a piperidinyl, or morpholin-4-yl, or pyrrolidin-1-yl, or azetidin-1-yl, or azepin-1-yl, or pyridinyl, or quinolinyl, or thienyl, or pyrazinyl, or furyl, or benzofuryl, or benzothienyl, or indolyl, or pyrimidinyl, or isoxazolyl, or phenoxazinyl, or phenoxathiinyl, or dibenzothienyl, or dibenzofuryl, or pyrrolyl, or naphthyl group, where each of these groups may optionally be substituted by one or more groups chosen from halogen atoms, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, hydroxy, amino, (C₁-C₃)dialkylamino or (C₃-C₈)cycloalkylamino groups, and where, of the two carbon-carbon bonds represented by , one is single and the other may be single or double,

in the form of base or of salt derived from addition to an acid.

2. **(currently amended)** Compound according to Claim 1, ~~characterized in that~~ wherein R either represents a halogen atom or a phenyl group substituted by one or more groups chosen from halogen atoms and (C₁-C₆)alkyl, (C₁-C₆)alkoxy, nitro, amino, trifluoromethyl, cyano, hydroxy, acetyl or methylenedioxy groups, or represents a pyridinyl group or a thienyl group or an indolyl group or a pyrimidinyl group optionally substituted by one or more (C₁-C₆)alkoxy groups.

3. **(currently amended)** ~~Medicament characterized in that it consists~~ A method for the treatment or prevention of disorders linked to a dysfunction of the nicotinic receptors which

comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 1.

4. **(currently amended)** Pharmaceutical composition ~~characterized in that it~~ which comprises a compound according to Claim 1, together with an excipient.

5. **(new)** A method for the treatment or prevention of disorders linked to a dysfunction of the nicotinic receptors which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 2.

6. **(new)** Pharmaceutical composition which comprises a compound according to Claim 2, together with an excipient.